Results 71 to 80 of about 41,221 (142)

Safety and Efficacy of Extended Interval Dosing for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer During the COVID-19 Pandemic. [PDF]

Clin Lung Cancer, 2022
Hijmering-Kappelle LBM, Hiltermann TJN, Bensch F.   +2 more
europepmc   +1 more source

Clinical impact of Ocrelizumab extended interval dosing during the COVID-19 pandemic and associations with CD19⁺B-cell repopulation. [PDF]

Mult Scler Relat Disord, 2021
Sahi NK, Abidi SMA, Salim O, Abraham R, Kalra S, Al-Araji A.   +5 more
europepmc   +1 more source

Extended-Interval Dosing and Discontinuation of Dupilumab in Atopic Dermatitis: A Real-World Retrospective Study. [PDF]

J Dermatol
Saito R, Sasaki W, Watanabe H, Hashimoto M, Kamigaki R, Nagiri K, Tanaka A.   +6 more
europepmc   +1 more source

A Pharmacokinetic Analysis of Tobramycin in Patients Less than Five Years of Age with Cystic Fibrosis: Assessment of Target Attainment with Extended-Interval Dosing through Simulation. [PDF]

Antimicrob Agents Chemother, 2022
Downes KJ, Grim A, Shanley L, Rubenstein RC, Zuppa AF, Gastonguay MR.   +5 more
europepmc   +1 more source

Dupilumab Extended Interval Dosing in Chronic Rhinosinusitis With Nasal Polyps: A Systematic Review and Meta-analysis. [PDF]

Otolaryngol Head Neck Surg
Alqutub A, Herzallah AI, Alqutub S, Assiri SA, Herzallah IR.   +4 more
europepmc   +1 more source

Individual Variability of CD19+ B-Cell Repopulation in People With Multiple Sclerosis Treated With Extended Interval Dosing of Ocrelizumab. [PDF]

Eur J Neurol
Hogenboom L, Schoof LG, Gelissen LMY, Mostert J, van Rooij L, Hoitsma E, van Munster CEP, van Eijk J, Kalkers NF, Adriani KS, Vennegoor A, Arts IMP, Mensing L, Eurelings M, de Gans K, Gerlach O, Hoogervorst ELJ, Kloosterziel ME, Kragt JJ, Portier RP, Smets I, van Geel BM, Nielsen J, Roosendaal CM, Piet JR, Zeinstra E, Groeneveld ON, van Oosten BW, de Jong BA, Uitdehaag BMJ, Strijbis EMM, Lissenberg-Witte BI, Killestein J, van Kempen ZLE.   +33 more
europepmc   +1 more source

Optimizing Rituximab Maintenance Therapy: Outcomes of Extended-Interval Dosing in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. [PDF]

J Clin Med Res
Kittipadakul S, Ongphichetmetha T, Siritho S, Uawithya E, Prayoonwiwat N, Rattanathamsakul N, Jitprapaikulsan J.   +6 more
europepmc   +1 more source

Adoption of Extended-Interval Dosing of Single-Agent Pembrolizumab and Comparative Effectiveness vs Standard Dosing in Time-to-Treatment Discontinuation.

JAMA Oncol, 2022
Strohbehn GW, Holleman R, Burns J, Klamerus ML, Kelley MJ, Kerr EA, Ramnath N, Hofer TP.   +7 more
europepmc   +1 more source

Natalizumab-Associated Progressive Multifocal Leukoencephalopathy After Natalizumab Extended Interval Dosing Therapy in Japan. [PDF]

Neurol Neuroimmunol Neuroinflamm
Takahashi K, Nakahara J, Miura Y, Ae R, Nakamichi K, Harada M, Mori K, Sanjo N, Yukitake M, Yokote H, Hamaguchi T, Yamada M, Takao M.   +12 more
europepmc   +1 more source

Extended-interval dosing of rituximab/ocrelizumab is associated with a reduced decrease in IgG levels in multiple sclerosis. [PDF]

Neurotherapeutics
Rigollet C, Freeman SA, Perriguey M, Stellmann JP, Graille-Avy L, Lafontaine JC, Lemarchant B, Alberto T, Demortière S, Boutiere C, Rico A, Hilézian F, Durozard P, Pelletier J, Maarouf A, Zéphir H, Audoin B.   +16 more
europepmc   +1 more source